Krystal Biotech (NASDAQ:KRYS) Earns "Buy" Rating from HC Wainwright

Key Points

• Krystal Biotech's stock has been given a "buy" rating by HC Wainwright, with a price target of $240.00, indicating a potential upside of 60% from its current price.
• In recent reports, multiple analysts have issued various price targets for Krystal Biotech, with an average target price of $211.33 based on eight buy ratings and one strong buy rating.
• The company reported $1.20 earnings per share for the last quarter, falling short of the $1.38 consensus estimate, along with revenues of $88.18 million against expectations of $98.66 million.

Krystal Biotech (NASDAQ:KRYS - Get Free Report)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $240.00 price target on the stock. HC Wainwright's price objective suggests a potential upside of 60.00% from the company's current price.

Other equities analysts have also recently issued research reports about the stock. Guggenheim dropped their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Bank of America lowered their price target on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a report on Tuesday. Chardan Capital reaffirmed a "buy" rating and issued a $219.00 price target on shares of Krystal Biotech in a report on Friday. Finally, Citigroup reaffirmed a "neutral" rating and issued a $176.00 price target (up previously from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Krystal Biotech has an average rating of "Buy" and an average target price of $211.33.

Krystal Biotech Stock Down 2.1%

NASDAQ KRYS opened at $150.00 on Friday. The company has a market capitalization of $4.33 billion, a price-to-earnings ratio of 36.06 and a beta of 0.67. Krystal Biotech has a twelve month low of $122.80 and a twelve month high of $219.34. The stock has a fifty day simple moving average of $137.92 and a 200 day simple moving average of $155.77.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). The company had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. Research analysts expect that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 13,435 shares of the company's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. This represents a 0.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last three months, insiders have sold 49,800 shares of company stock worth $7,487,943. Insiders own 13.70% of the company's stock.

Institutional Trading of Krystal Biotech

Several large investors have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock worth $103,764,000 after buying an additional 365,304 shares in the last quarter. Nuveen LLC purchased a new stake in Krystal Biotech during the first quarter worth $42,223,000. Norges Bank purchased a new stake in Krystal Biotech during the fourth quarter worth $34,391,000. Braidwell LP boosted its holdings in Krystal Biotech by 99.9% during the first quarter. Braidwell LP now owns 400,744 shares of the company's stock worth $72,254,000 after buying an additional 200,244 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new stake in Krystal Biotech during the first quarter worth $33,455,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.